Average steps per day as marker of treatment response with anti-CGRP mAbs in adults with chronic migraine: a pilot study

Frederik Thal Jantzen, Basit Ali Chaudhry, Samaira Younis, Ina Nørgaard, Christopher Kjær Cullum, Thien Phu Do, Dagmar Beier, Faisal Mohammad Amin*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

2 Downloads (Pure)

Abstract

Physical activity can worsen migraine, leading to reduced activity levels in adults with chronic migraine. This study investigated the change in average steps per day, as a surrogate marker of physical activity, in adults with chronic migraine successfully treated with monoclonal antibodies against calcitonin gene-related peptide or its receptor. Data were obtained from adults with chronic migraine, who were classified as responders to preventive treatment with monoclonal antibodies. The primary endpoint was the difference in a mean number of steps per day between the 3 months prior to treatment initiation and the first 3 months after treatment initiation. The secondary endpoint was the correlation between the change in steps per day and the change in monthly migraine days. Twenty-two (20 females) participants with a median age of 48.5 years were enrolled. The median number of steps per day increased from 4421 at baseline to 5241 after treatment (P = 0.039). We found a positive correlation between the increase in steps per day and the treatment response (P = 0.013). In conclusion, an increase in physical activity, based on steps per day, positively correlated with treatment response to monoclonal antibodies. Automatically registered daily step count data might be used to monitor physical activity as a response to preventive treatment in adults with chronic migraine.

Original languageEnglish
Article number18068
JournalScientific Reports
Volume14
Issue number1
Number of pages6
ISSN2045-2322
DOIs
Publication statusPublished - 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2024.

Keywords

  • CGRP
  • Headache
  • Migraine with aura
  • Migraine without aura
  • Monoclonal CGRP antibodies
  • PRO

Cite this